These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 24477320)

  • 1. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
    Metz M; Ohanyan T; Church MK; Maurer M
    JAMA Dermatol; 2014 Mar; 150(3):288-90. PubMed ID: 24477320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
    Wieder S; Maurer M; Lebwohl M
    Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
    Har D; Patel S; Khan DA
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):126-9. PubMed ID: 26093778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of idiopathic chronic cold urticaria with omalizumab: report of 3 cases.
    Le Moing A; Bécourt C; Pape E; Dejobert Y; Delaporte E; Staumont-Sallé D
    J Am Acad Dermatol; 2013 Aug; 69(2):e99-101. PubMed ID: 23866899
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-life experiences with omalizumab for the treatment of chronic urticaria.
    Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?
    Tontini C; Marinangeli L; Cognigni M; Bilò MB; Antonicelli L
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):147-8. PubMed ID: 26048249
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of omalizumab in the treatment of chronic urticaria.
    Stitt JM; Dreskin SC
    Immunotherapy; 2014; 6(6):691-7. PubMed ID: 25186602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
    Labrador-Horrillo M; Valero A; Velasco M; Jáuregui I; Sastre J; Bartra J; Silvestre JF; Ortiz de Frutos J; Gimenez-Arnau A; Ferrer M
    Expert Opin Biol Ther; 2013 Sep; 13(9):1225-8. PubMed ID: 23875845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in chronic urticaria: a retrospective series of 15 cases.
    Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E
    Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria.
    Nettis E; Di Leo E; Foti C; Cegolon L; Vacca A
    J Am Acad Dermatol; 2018 Jun; 78(6):1211-1213. PubMed ID: 29203434
    [No Abstract]   [Full Text] [Related]  

  • 20. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.